Blood-Based Inflammatory Indices in COVID-19 Patients with Different Degrees of Lung Involvement

Document Type : Original Article(s)

Authors

1 Associate Professor, Department of Immunology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

2 Medical Student, Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran

3 Assistant Professor, Department of Radiology, Faculty of Medicine AND Iranian Research Center on Healthy Aging, Sabzevar University of Medical Sciences, Sabzevar, Iran

4 Assistant Professor, Department of Internal Medicine, Faculty of Medicine AND Leishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

5 Assistant Professor, Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

Abstract

Background: This study aimed to compare some inflammatory indices in COVID-19 patients with different degrees of lung involvement.
Methods: In this descriptive-analytical study, 301 patients with COVID-19 who were hospitalized in Vasei-Sabzevar Hospital from October 2021 to March 2022 were included. Patients were divided into mild, moderate, and severe groups based on the CT scan findings and the severity of lung involvement. Based on complete blood count (CBC) results, neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), platelet/lymphocyte (PLR) ratios, and systemic inflammation index (SII) were calculated.
Findings: Based on CT scan findings, mild, moderate, and severe lung involvement was observed in 39%, 37%, and 24% of patients, respectively. NLR, PLR, and SII indices were significantly higher in severe lung involvement compared to other groups (P < 0.05). The MLR was significantly higher in severe lung involvement than in moderate involvement. Mortality in severe lung involvement was significantly higher than in moderate and mild groups (41% vs. 2% and 5%, respectively) (P < 0.001). Also, 13% of patients died. There was no significant difference between mortality and patient’s gender.
Conclusion: NLR, PLR, MLR, and SII are related to COVID-19 severity, and these indices amounts in severe lung involvement are more than moderate and mild involvement. These findings show the importance of these indices in determining the COVID-19 prognosis.

Highlights

Mohammad-Shafi Mojadadi: Google Scholar, PubMed

Mohammad Reza Aram: Google Scholar, PubMed

Ramin Shahraini: Google Scholar, PubMed

Abolfazl Shakiba: Google Scholar, PubMed

Saeideh Sadat Shobeiri: Google Scholar, PubMed

Keywords

Main Subjects


  1. World Health Organization. Novel coronavirus-China. [Online]. [cited 2020 Jan 12]; Avilable from: URL: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON233
  2. Fouladseresht H, Doroudchi M, Rokhtabnak N, Abdolrahimzadehfard H, Roudgari A, Sabetian G, et al. Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. Cytokine Growth Factor Rev 2021; 58: 32-48.
  3. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013; 11(12): 836-48.
  4. Fouladseresht H, Ghamar Talepoor A, Eskandari N, Norouzian M, Ghezelbash B, Beyranvand MR, et al. Potential immune indicators for predicting the prognosis of COVID-19 and trauma: Similarities and disparities. Front Immunol 2022; 12: 785946.
  5. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020; 92(4): 418-23.
  6. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395(10223): 470-3.
  7. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020; 202(5): 756-9.
  8. Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, Meyer RF, et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis 2004; 10(2): 311-6.
  9. Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 2010; 48(8): 2940-7.
  10. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020; 295(3): 715-21.
  11. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol 2020; 92(4): 424-32.
  12. Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol 2020; 30(8): 4407-16.
  13. Shi H, Zuo Y, Yalavarthi S, Gockman K, Zuo M, Madison JA, et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. J Leukoc Biol 2021; 109(1): 67-72.
  14. Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol 2020; 38(8): 970-9.
  15. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 2020; 26(6): 842-4.
  16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
  17. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020; 27(6): 992-1000. e3.
  18. Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case-control study. Clin Infect Dis 2014; 59(11): 1554-8.
  19. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol 2003; 34(8): 743-8.
  20. Nicholls J, Dong XP, Jiang G, Peiris M. SARS: clinical virology and pathogenesis. Respirology 2003; 8 Suppl(Suppl 1): S6-8.
  21. AlBshabshe A, Al-Asmary M, Al-Harthi M, Al-Ahmari H, Al-Ahmari M, Rabea MM, et al. Usage of venous thromboembolism prophylaxis at a tertiary care hospital in Aseer region of Saudi Arabia. Saudi Med J 2015; 36(11): 1367-8.
  22. Eissa M, Shaarawy S, Abdellateif MS. The role of different inflammatory indices in the diagnosis of COVID-19. Int J Gen Med 2021; 14: 7843-53.
  23. Seyit M, Avci E, Nar R, Senol H, Yilmaz A, Ozen M, et al. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. Am J Emerg Med 2021; 40: 110-4.
  24. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta 2020; 507: 174-80.
  25. Khartabil T, Russcher H, van der Ven A, De Rijke Y. A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients. Crit Rev Clin Lab Sci 2020; 57(6): 415-31.
  26. Feng Z, Yu Q, Yao S, Luo L, Duan J, Yan Z, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun 2020; 11(1): 4968
  27. Song CY, Xu J, He JQ, Lu YQ. COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients. MedRxiv 2020.03.05.20031906
  28. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
  29. Yang P, Ding Y, Xu Z, Pu R, Li P, Yan J, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. Medrxiv 2020.02.28.20028068
  30. Chandler CM, Reid MC, Cherian S, Sabath DE,
    Edlefsen KL. Comparison of blood counts and markers of inflammation and coagulation in patients with and without COVID-19 presenting to the Emergency Department in Seattle, WA. Am J Clin Pathol 2021; 156(2): 185-97.
  31. Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One 2020; 15(7): e0235458.
  32. Nalbant A, Demirci T, Kaya T, Aydın A, Altındiş M, Güçlü E. Can prognostic nutritional index and systemic immune-inflammatory index predict disease severity in COVID-19? Int J Clin Pract 2021; 75(10): e14544.
  33. Man MA, Rajnoveanu RM, Motoc NS, Bondor CI, Chis AF, Lesan A, et al. Neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients. PLoS One 2021; 16(6): e0252599.
  34. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
  35. Yu H, Li D, Deng Z, Yang Z, Cai J, Jiang L, et al. Total protein as a biomarker for predicting coronavirus disease-2019 pneumonia. [Online]. [cited 2020]; Available from: URL:

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3551289

  1. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8.
  2. Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The systemic inflammation index on admission predicts in-hospital mortality in COVID-19 patients. Molecules 2020; 25(23): 5725.
  3. Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID-19 mortality-preliminary results. MedRxiv. 2020.02.24.20027268.
  4. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health 2020; 8: 152.
  5. Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, et al. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. Radiol Med 2020; 125(5): 461-4.
  6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
  7. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020; 368: m1198.